Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
MULTIFUGE (piperazine citrate) is an oral anthelmintic syrup approved in 1954 for treating parasitic worm infections. The drug works by paralyzing parasites, enabling their expulsion from the gastrointestinal tract. It represents a legacy small-molecule therapeutic with decades of clinical use.
Declining revenue and approaching loss of exclusivity signal a contracting team and reduced headcount opportunities on the brand.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job openings reflect the product's mature, declining lifecycle and limited organizational investment. Career opportunities are constrained; roles that do exist focus on managing generic transition and maintaining market share in legacy indications.
Worked on MULTIFUGE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.